A pharmaceutical composition containing as the active ingredient a compound which presents low-density lipoproteins (LDL) represented by the compounds of formula (I) from being negatively charged. This composition inhibits the LDL from undergoing denaturation (oxidation) necessary for the recognition by a scavenger acceptor, and is used for treating arteriosclerosis, peptic ulcer, cancer, ischemic organ disease, inflammation and pulmonary silicosis.
作者:ANTONINI, I.、CRISTALLI, G.、FRANCHETTI, P.、GRIFANTINI, M.、MARTELLI, S.
DOI:——
日期:——
Pioneering 4,11-Dioxo-4,11-dihydro-1<i>H</i>-anthra[2,3-<i>d</i>]imidazol-3-ium Compounds as Promising Survivin Inhibitors by Targeting ILF3/NF110 for Cancer Therapy